Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19

NCT05381519 is registered in ClinicalTrials.gov with Wuhan Institute of Biological Products Co., Ltd as lead sponsor.

NCT NCT05381519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05381519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19
Lead sponsor
Wuhan Institute of Biological Products Co., Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2022
Completion date
September 30, 2022
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19